Breast Cancer

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

### Pre-Op Therapy

- **Endocrine Therapy**
  - No Trial Currently Available

### Surgical Therapy

**No Trial Currently Available**

**IRB# 9340**
- Phase II breast conservation surgery and radiation therapy study
- IRB 15164: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

### Adjuvant Therapy

- **No Trial Currently Available**

### 1st line MBC Therapy

- **No Trial Currently Available**

### 2nd line MBC Therapy

- **IRB # 9076**
  - Phase III study in postmenopausal women that have progressed on or after mTOR therapy

### 3rd line MBC Therapy

- **No Trial Currently Available**

### “Heavily Pre-treated” Therapy

- **No Trial Currently Available**

### ER/PR-POSITIVE HER2 NEGATIVE

- **IRB# 6256**
  - ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

### HER2 POSITIVE

- **IRB# 6256**
  - ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

### “TRIPLE NEGATIVE” EP/PR –NEGATIVE HER2-NEGATIVE

- **IRB# 6256**
  - ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

### IRB #15366
- Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
  - (Applies to Adjuvant, 1st line and beyond HER2+ MBC therapy)

### IRB #11351
- Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer

### IRB # 9076
- Phase III study in postmenopausal women that have progressed on or after mTOR therapy

### IRB #15176
- A Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

10/6/2016

www.ohsu.edu/cancer